Joe Rabin, Editor

About the Author Joe Rabin, Editor

Joe is an intern at Smarter Analyst. He has written on a broad range of topics, including: financial trading, career development, cybersecurity, gamification, network access control, recreation and more.

Endo International plc – Ordinary Shares (ENDP) Near-Term Challenges Offset 2Q Earnings Beat

Despite Endo International plc – Ordinary Shares (NASDAQ:ENDP) delivering a second-quarter earnings beat on Tuesday, with the management team forced to pull back …

Apple Inc. (AAPL) Monitor Sales Signal Unusually Strong Momentum, Tripadvisor (TRIP) Gets Price Target Cut

Analysts from Drexel Hamilton and Piper Jaffray are out delving into two major tech players: Apple Inc. (NASDAQ:AAPL) and Tripadvisor Inc (NASDAQ:TRIP).

Top Analyst Commends Pandora Media Inc (P) Initiatives to Expand User Base Following Growth Conference

Top analyst Michael Graham of Canaccord recently hosted a fireside chat with Pandora Media Inc (NYSE:P) CFO and interim CEO Naveen Chopra at …

Snap Inc (SNAP) Investors Shouldn’t Throw In The Towel Yet: Cantor

Cantor analyst Kip Paulson is out with a new research note on Snap Inc (NYSE:SNAP) ahead of the media mogul’s release of second quarter …

Michael Kors Holdings Ltd (KORS) Turnaround Plan on Track: Wells Fargo

It is no secret that online shopping has taken a toll on Michael Kors Holdings Ltd (NYSE:KORS). Once peddling the hottest luxury handbags on …

Oppenheimer Makes Drastic Price Target Cut for Zynerba Pharmaceuticals Inc Following Epilepsy Drug Setback

Upon releasing negative data for lead drug candidate transdermal CBD (ZYN002) on Monday, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) investors ran for the hills, sending …

Myokardia Inc (MYOK) Heart Drug Takes Next Beat Towards Finish Line; Cowen Boosts Price Target

Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …

Rodman & Renshaw Maintains Upbeat View of Gevo, Inc. (GEVO) on Back of 2Q Growth

Rodman & Renshaw analyst Amit Dayal is out with a new research note on shares of Gevo, Inc. (NASDAQ:GEVO), after the biofuel maker …

Is Teva Pharmaceutical Industries Ltd (ADR) (TEVA) at Rock Bottom? Maxim Weighs in

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) released a grim second quarter print last Thursday, revealing that the management team had lowered guidance across …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts